Gujarat Themis Biosyn QIP closes: ₹750 cr at ₹354

Key development

Gujarat Themis Biosyn Limited has finalised a Qualified Institutions Placement (QIP), allotting equity shares to eligible Qualified Institutional Buyers (QIBs) at an issue price of ₹354 per share. The Fund-Raising Committee approved the closure of the issue period on August 28, 2026. Alongside the completed QIP, the company has also disclosed that its Board of Directors will meet on September 1, 2026, to consider a fresh fund-raise proposal through a preferential issue of equity shares and or convertible warrants on a private placement basis.

The disclosures were made through regulatory filings with stock exchanges, referencing compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also noted that the proposed preferential issuance would be subject to shareholder approval and regulatory clearances under SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013.

QIP pricing and discount to floor price

The issue price for the QIP was fixed at ₹354 per equity share, including a premium of ₹353 per share (face value ₹1). The company had earlier fixed the regulatory floor price at ₹372.57 per share, and the final issue price represents a discount of ₹18.57 per share.

In percentage terms, the discount works out to 4.98% versus the floor price. The disclosures also state this pricing aligns with the maximum discount of up to 5% permitted under Regulation 176(1) of the SEBI ICDR Regulations, 2018.

Allotment size and proceeds reported

The company allotted 2,11,86,440 equity shares to eligible QIBs under the QIP. The total proceeds disclosed for the placement were ₹749,99,99,760, which is approximately ₹750 crore.

Separately, parts of the provided market snapshot also reference the QIP proceeds as ₹75 crore. The regulatory figure of ₹749,99,99,760 (approximately ₹750 crore) is explicitly stated alongside the final allotment count and price, and is presented as the aggregate proceeds raised under the QIP.

Shareholder approval and voting outcome

Shareholders approved the fund-raising measure through a postal ballot, with 99.97% voting in favour of the resolution to raise funds by issuing equity shares through a QIP. The voting data shared shows 77,845,234 votes in favour (99.97%) and 20,680 votes against (0.03%).

The company’s board had also approved opening the QIP with the floor price of ₹372.57 per share on August 25, 2026, following the conclusion of the postal ballot on August 22, 2026.

Change in Articles of Association

Gujarat Themis Biosyn also amended its Articles of Association after shareholder approval via a special resolution passed through the postal ballot dated August 22, 2026. The change targets Article 13(1), Clause (c), which governs the company’s ability to issue shares.

Under the revised clause, the company may issue shares to any persons, whether or not they include existing categories referenced elsewhere in Article 13, and may do so for cash or for non-cash consideration. The update also removed an earlier requirement that referenced valuation by a registered valuer, indicating a more flexible framework for future share issuances as described in the disclosure.

Capital structure impact after allotment

Following the QIP allotment, Gujarat Themis Biosyn reported an increase in its paid-up equity share capital. The paid-up equity share capital increased from ₹10,89,65,265 (10,89,65,265 shares) to ₹13,01,51,705 (13,01,51,705 shares).

The QIP shares carry a face value of ₹1 each, as stated in the market snapshot. The issue price of ₹354 per share includes a premium of ₹353 per share.

Institutional participation highlights

The market snapshot notes that Quant Small Cap Fund emerged as the largest single allottee with a 25.67% stake, as reported in the provided text. The disclosure in the prompt does not provide a full allottee list, but flags this institutional participation detail as a notable point.

Board meeting on September 1: preferential issue proposal

The company has scheduled a board meeting on September 1, 2026. The key agenda is to consider and approve a proposal to raise funds through a preferential issue of equity shares and or convertible warrants on a private placement basis.

The company has stated that the proposed fund-raise will require shareholder approval and regulatory clearances. It also disclosed that the trading window for designated persons and their immediate relatives remains closed and will continue to remain closed until 48 hours after the announcement of the outcome of the meeting.

Market impact: what the filings indicate

From a market structure perspective, the QIP was completed at a discount of 4.98% to the floor price, which is within the stated regulatory limit of up to 5%. The allotment increased the company’s paid-up equity capital to ₹13.015 crore, reflecting the additional shares issued.

The prompt also states that this capital injection would fund the company’s ₹2,700 crore global acquisitions and major ongoing capex and reduce overall balance sheet leverage. This point is presented as part of the provided snapshot and links the fund-raise to acquisition and investment plans mentioned in the text.

Company context

The prompt describes Gujarat Themis Biosyn as India’s first company to start commercial production of the anti-tuberculosis drug Rifampicin. This operational context is included alongside the capital-raising disclosures and frames the company within the pharmaceuticals and anti-infectives segment.

Key facts table

Timeline of events disclosed

What investors will watch next

The immediate next milestone is the September 1, 2026 board meeting where the company plans to consider a preferential issue of equity shares and or convertible warrants. Any decision on structure, pricing, and size of the proposed fund-raise would require subsequent disclosures and approvals as indicated.

Separately, the company’s updated Articles of Association and the completion of the QIP provide a clearer legal and capital framework for additional issuances, subject to the stated regulatory processes. The trading window restrictions will remain in place until 48 hours after the company announces the board meeting outcome, as per the disclosure.